Correlation Between Arcus Biosciences and Apogee Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Arcus Biosciences and Apogee Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcus Biosciences and Apogee Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arcus Biosciences and Apogee Therapeutics, Common, you can compare the effects of market volatilities on Arcus Biosciences and Apogee Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcus Biosciences with a short position of Apogee Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcus Biosciences and Apogee Therapeutics,.

Diversification Opportunities for Arcus Biosciences and Apogee Therapeutics,

0.31
  Correlation Coefficient

Weak diversification

The 3 months correlation between Arcus and Apogee is 0.31. Overlapping area represents the amount of risk that can be diversified away by holding Arcus Biosciences and Apogee Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apogee Therapeutics, and Arcus Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcus Biosciences are associated (or correlated) with Apogee Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apogee Therapeutics, has no effect on the direction of Arcus Biosciences i.e., Arcus Biosciences and Apogee Therapeutics, go up and down completely randomly.

Pair Corralation between Arcus Biosciences and Apogee Therapeutics,

Given the investment horizon of 90 days Arcus Biosciences is expected to generate 17.94 times less return on investment than Apogee Therapeutics,. But when comparing it to its historical volatility, Arcus Biosciences is 1.2 times less risky than Apogee Therapeutics,. It trades about 0.01 of its potential returns per unit of risk. Apogee Therapeutics, Common is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest  1,700  in Apogee Therapeutics, Common on September 23, 2024 and sell it today you would earn a total of  3,071  from holding Apogee Therapeutics, Common or generate 180.65% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy73.64%
ValuesDaily Returns

Arcus Biosciences  vs.  Apogee Therapeutics, Common

 Performance 
       Timeline  
Arcus Biosciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Arcus Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Arcus Biosciences is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.
Apogee Therapeutics, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Apogee Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Arcus Biosciences and Apogee Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Arcus Biosciences and Apogee Therapeutics,

The main advantage of trading using opposite Arcus Biosciences and Apogee Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcus Biosciences position performs unexpectedly, Apogee Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apogee Therapeutics, will offset losses from the drop in Apogee Therapeutics,'s long position.
The idea behind Arcus Biosciences and Apogee Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Other Complementary Tools

Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.